

Reliance Home Finance

Sector: Housing Finance / Small Cap | Earnings Update – 4QFY18

BUY

26 April 2018


Background: Reliance Home Finance (RELHF), a Reliance group (ADAG) company, formed in 2008, is a non deposit taking housing finance company, focused on providing financing products for the LMI to HMI segment in India, primarily in Tier II and Tier III cities and towns, with more thrust on the self-employed segment. Its loan book portfolio is diversified with across - Home loans (30%), Affordable Housing (21%), LAP (21%) and Construction Finance (28%) segments. The company has its presence in over 125 locations spread over 54 cities, with over 45000 client accounts.

Sensex	34,714
Nifty	10,618
Price	INR 63
Target Price	INR 100
Recommendation	BUY
<hr/>	
52 Week High/Low	INR 923/552
Bloomberg / Reuters	RELHOME IN / RLIC BO
Equity (shares in mn)	485.06
Mkt. Cap in bn	INR 30.29/ \$ 0.45
Avg. Daily Vol. ('000)	1115.74
Avg. Daily Vol. (mn)	INR 69.68 / \$ 1.04

Shareholding	Sep 17	Dec 17	Mar 18
Promoters (%)	74.99	74.99	74.99
FII (%)	9.88	7.49	5.98
DII (%)	4.01	5.27	5.44
Others (%)	11.12	12.25	13.59
Pledge (% of promoter holding)	10.85	22.17	21.62

Valuation Summary (INR bn)			
Y/E March	2018	2019E	2020E
Net Interest Inc	5.6	9.2	11.6
Other Inc	0.6	1.7	2.1
Pre Prov Profit	3.6	7.5	9.4
PAT	1.8	4.5	6.0
EPS	3.7	9.4	12.3
EPS growth (%)	6.6	151.2	31.2
PE	16.8	6.7	5.1
P /BV	2.0	1.5	1.2
Div Yield (%)	0.6	1.0	1.0
ROA (%)	1.3	2.6	2.8
ROE (%)	13.9	25.8	26.4
CAR (%)	19.7	21.9	22.3

Performance %	1M	3M	6M
RELHF	6.4	-23.2	-22.9
Sensex	4.9	-3.7	4.7



Robust growth in AUM led by high yielding segments; PBT up by 116%YoY

- RELHF's loan book recorded robust growth of 33%YoY (10.2% QoQ) and stood at INR 163.8bn, largely driven by growth in Affordable Housing Segment (35% YoY). In FY18 disbursements grew by 19% YoY to INR 87bn. The management expects its AUM to grow by 45% CAGR over FY19-21E.
- Self employed segment, being the niche area for the company, constituted 75% of Home loan disbursements in 4QFY18. Higher growth in high yielding segments like self employed and affordable housing segments, helped in marginal increase in the average yield to 11.6% from 11.5% in 3QFY18.
- With increase in the share of NCDs in Borrowings (42%), Cost of funds dipped by 70bps YoY (-20bps QoQ) to 8.6%. This coupled with robust growth in loan book (predominantly the high yielding segments) led to a 50bps YoY expansion in NIMs (currently at 3.9%). Going forward, the management expects NIMs to remain in the range of 3.5-3.9%.
- Asset quality remained intact, with the reported GNPA's at (same levels as 3QFY18) a healthy 0.8% and NNPA at 0.42%. PCR stood at 47% up from 26% in 4QFY17. With focus on small ticket lending, and strict policy measures (w.r.t credit appraisal) in place, the management expects NPAs to remain at current levels.
- Net Interest Income skyrocketed by 95% YoY to INR 1.4bn. However other income saw a de-growth of 38.2% YoY. Although the impact of the same was offset by a 9.3% YoY de-growth in opex and a 2.2% YoY decline in provisions. Consequently Profit before tax grew by 116% YoY to INR 900mn. Due to the availability of Deferred tax Assets until FY17, PAT saw a decline of 47% YoY (up sequentially buy 23.9%).
- Amongst the 11 new branches set up in FY18, 4 were low cost affordable branches, which along with the operational efficiency setting in brought the cost to income ratio to 38% in 4QFY18 from 55% in 4QFY17. Going forward the company plans to extend its reach to over 200 locations (from current 125 locations) and open 75 new branches over FY19-20E, yet trying to maintain C/I ratio in the current levels with low cost affordable branches.
- The board has recommended a dividend of INR 1/share (face value INR 10/share), yielding 1.6% at CMP.

Valuation: Robust loan book growth, coupled with improving cost efficiency, and well maintained asset quality should act as an catalyst to spur the earnings growth of the company. The stock is currently trading at 1.2X P/BV and 5.1X P/E of FY20E. We maintain our BUY rating on Reliance Home Finance with revised target price of INR 100, assigning a P/BV of 1.9X.

Risks: Rising bond yields could put pressure on NIMs; asset quality deterioration as the share of riskier segment increases; rising competition in HFC space.

Results Summary 4QFY18

Y/E March (INR mn)	4QFY18	4QFY17	YoY Growth	3QFY18	QoQ Growth
Net Interest Income	1702.0	1000.0	70.2%	1350.0	26.1%
Other Income	170.0	460.0	-63.0%	200.0	-15.0%
Pre Provisioning Profit	1170.0	686.0	70.6%	849.0	37.8%
PAT	570.0	1080.0	-47.2%	460.0	23.9%
Cost / Income (%)	37.5	53.0		45.2	
Gross NPA (%)	0.8	0.8		0.8	
Net NPA (%)	0.4	0.6		0.4	
Prov Coverage ratio (%)	47.0	26.0		47.0	
CAR (%)	19.7	19.3		21.5	

DISCLOSURES/ APPENDIX
I. ANALYST CERTIFICATION

I, **Keerthi.S** hereby certify (1) that the views expressed in this research report accurately reflect my personal views about any or all of the subject securities or issuers referred to in this research report, (2) No part of my compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in this research report by Cholamandalam Securities Limited or its Group/associates companies. (3) has taken reasonable care to achieve and maintain independence and objectivity in making any recommendations.

Disclosure of Interest Statement	Update
Analyst holding in the stock	No
Served as an officer, director or employee	No

II. ISSUER SPECIFIC REGULATORY DISCLOSURES, Unless specifically mentioned in Point No. 9 below:

1. The Research Analyst(s), Cholamandalam Securities Limited (CSL), Associate of Analyst or his relative does not have any financial interest in the company(ies) covered in this report.
2. The Research Analyst, CSL or its associates or relatives of the Research Analyst associates collectively do not hold more than 1% of the securities of the company (ies) covered in this report as of the end of the month immediately preceding the distribution of the research report.
3. The Research Analyst, his associate, his relative and CSL do not have any other material conflict of interest at the time of publication of this research report.
4. The Research Analyst, CSL and its associates have not received compensation for investment banking or merchant banking or brokerage services or for any other products or services from the company(ies) covered in this report, in the past twelve months.
5. The Research Analyst, CSL or its associates have not managed or co-managed in the previous twelve months, a private or public offering of securities for the company (ies) covered in this report. \
6. CSL or its associates have not received compensation or other benefits from the company(ies) covered in this report or from any third party, in connection with the research report.
7. The Research Analyst has not served as an Officer, Director or employee of the company (ies) covered in the Research report.
8. The Research Analyst and CSL has not been engaged in market making activity for the company(ies) covered in the Research report.
9. Details CSL, Research Analyst and its associates pertaining to the companies covered in the Research report:

Sr.No.	Particulars	Yes/No
1	Whether compensation has been received from the company(ies) covered in the Research report in the past 12 months for investment banking transaction by CSL	No
2	Whether Research Analyst, CSL or its associates or relatives of the Research Analyst associates collectively hold more than 1% of the company(ies) covered in the Research report	No
3	Whether compensation has been received by CSL or its associates from the company(ies) covered in the Research report	No
4	CSL or its associates have managed or co-managed in the previous twelve months a private or public offering of securities for the company(ies) covered in the Research report	No
5	Research Analyst, his associate, CSL or its associates have received compensation for investment banking or merchant banking or brokerage services or for any other products or services from the company(ies) covered in the Research report, in the last twelve month	No

10. There are no material disciplinary action that been taken by any regulatory authority impacting equity research analysis activities.

STOCK RATINGS

BUY : The stock's total return is expected to exceed 15 % over the next 12 months.

OUT PERFORMER: The stock's total return is expected to be within 5-15% over the next 12 months.

MARKET PERFORMER : The stock's total return is expected to be between -5% to +5% over the next 12 months.

UNDER PERFORMER: The stock's total return is expected to be between -15% to -5% over the next 12 months.

SELL: The stock's total return is expected to more than -15% over the next 12 months.

III. DISCLAIMER

The information and opinions contained herein have been compiled or arrived at, based upon information obtained in good faith from sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness.

This document is for information purposes only. This report is based on information that we consider reliable, but we do not represent that it is accurate or complete, and one should exercise due caution while acting on it. Descriptions of any company or companies or their securities mentioned herein are not complete and this document is not, and should not be construed as an offer or solicitation of an offer to buy or sell any securities or other financial instruments.

Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. All opinions, projections and estimates constitute the judgment of the author as on the date of the report and these, plus any other information contained in the report, are subject to change without notice. Prices and availability of financial instruments also are subject to change without notice. This report is intended for distribution to institutional investors.

This report is not directed to or intended for display, downloading, printing, reproducing or for distribution to or use by, any person or entity that is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, reproduction, availability or use would be contrary to law or regulation or what would subject to CSL or its associates to any registration or licensing requirement within such jurisdiction. If this report is inadvertently sent or has reached any individual in such country, especially, USA, the same may be ignored and brought to the attention of the sender. Neither this document nor any copy of it may be taken or transmitted into the United State (to U.S. Persons), Canada, or Japan or distributed, directly or indirectly, in the United States or Canada or distributed or redistributed in Japan or to any resident thereof.

Any unauthorized use, duplication, redistribution or disclosure of this report including, but not limited to, redistribution by electronic mail, posting of the report on a website or page, and/or providing to a third party a link, is prohibited by law and will result in prosecution. The information contained in the Report is intended solely for the recipient and may not be further distributed by the recipient to any third party.

CSL generally prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, CSL generally prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover. Our salespeople, traders, and other professionals or associates may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein. Our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

The views expressed in this research report reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report. The compensation of the analyst who prepared this document is determined exclusively by CSL however, compensation may relate to the revenue of CSL, of which sales and trading are a part. Research analysts and sales persons of CSL may provide important inputs to its affiliated company(ies).

Foreign currencies denominated securities, wherever mentioned, are subject to exchange rate fluctuations, which could have an adverse effect on their value or price, or the income derived from them. In addition, investors in securities such as ADRs, the values of which are influenced by foreign currencies effectively assume currency risk. CSL, its directors, analysts or employees do not take any responsibility, financial or otherwise, of the losses or the damages sustained due to the investments made or any action taken on basis of this report including but not restricted to fluctuation in the prices of shares and bonds, changes in the currency rates, diminution in the NAVs, reduction in the dividend or income, etc

CSL and its associates, officers, directors, and employees subject to the information given in the disclosures may: (a) from time to time, have long or short positions in, and buy or sell the securities thereof, of company (ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation (financial interest) or act as a market maker in the financial instruments of the company (ies) discussed herein or act as advisor or lender / borrower to such company (ies) or have other potential material conflict of interest with respect to any recommendation and related information and opinions. The views expressed are those of the analyst and the Company may or may not subscribe to the views expressed therein.

CSL, its associates and any third party involved in, or related to, computing or compiling the information hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any of this information. Without limiting any of the foregoing, in no event shall CSL, any of its associates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind. The Company accepts no liability whatsoever for the actions of third parties.

The Report may provide the addresses of, or contain hyperlinks to, websites. Except to the extent to which the Report refers to website material of the Company, the Company has not reviewed the linked site. Accessing such website or following such link through the report or the website of the Company shall be at your own risk and the Company shall have no liability arising out of, or in connection with, any such referenced website

CSL shall not be liable for any delay or any other interruption which may occur in presenting the data due to any technical glitch to present the data. In no event shall the CSL be liable for any damages, including without limitation, direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by CSL through this presentation.

Neither CSL, nor any of its other group companies or associates, shall be responsible for any decisions taken on the basis of this report. Investors are advised to consult their Investment and Tax consultants before taking any investment decisions based on this report.

RESEARCH			
Sathanarayanan M	Consumption	+91-44 - 3000 7361	sathanarayananm@chola.murugappa.com
Mugilan K	Auto Ancillary, Technicals	+91-44 - 3000 7353	mugilank@chola.murugappa.com
Keerthi S	Banking & Financial Services	+91-44 - 3000 7363	keerthi@chola.murugappa.com
Ashish M	Associate - IT	+91-44 - 3000 7360	ashishm@chola.murugappa.com
Muthu Kumar J	Associate- Research	+91-44 - 3000 7360	muthukumarj@chola.murugappa.com
INSTITUTIONAL SALES			
Venkat Chidambaram	Head of FII Business & Corporate Finance*	+91-44 - 24473310	venkatc@chola.murugappa.com
Lakshmanan T S P	Chennai	+91-9840019701	lakshmanantsp@chola.murugappa.com
Kishore K Ganti	Mumbai	+91-22-26597239	kishorekg@chola.murugappa.com
Bhavesh Katariya	Mumbai	+91-9860297739	bhaveshgk@chola.murugappa.com
Sudhanshu Kumar	Institutional Equities*	+91 - 9953175955	sudhanshuk@chola1.murugappa.com
Balaji H	Compliance Officer	044 - 30007226	balajih@chola.murugappa.com

*Employees of Business Partner - RCCR